Hodgkin lymphoma: trials for referral
158 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
158 trials shown
Phase 145 sites
RecruitingGermany, Spain, France, United Kingdom, Italy, Japan
NCT07226843
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Eli Lilly and Company
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 112 sites
RecruitingUnited States
NCT06150664
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 142 sites
By invitation onlyAustralia, Belgium, Denmark, Spain, France, United Kingdom
NCT06788509
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT03125642
Auto Stem Cell Transplant for Lymphoma Patients
Masonic Cancer Center, University of Minnesota
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 128 sites
RecruitingAustralia, Spain, France, Italy, Poland, United States
NCT07691606
A Study of ARC-02 in B-cell NHL
Taiho Oncology, Inc.
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/26 sites
RecruitingUnited States
NCT03681561
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Veronika Bachanova
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT02727803
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/261 sites
RecruitingArgentina, Australia, Brazil, Canada, Chile, China
NCT07519772
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Merck Sharp & Dohme LLC
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT02508038
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 23 sites
RecruitingUnited States
NCT06059391
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT04099966
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Mitchell Cairo
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 210 sites
RecruitingUnited States
NCT03618550
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 13 sites
RecruitingUnited States
NCT07020533
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 26 sites
RecruitingUnited States
NCT07021989
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Michael Spinner, MD
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govPhase 282 sites
RecruitingAustralia, Brazil, Canada, China, Germany, Denmark
NCT06526793
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
AstraZeneca
Registry updated 14 Oct 2026
Registry record: ClinicalTrials.govPhase 1/236 sites
RecruitingAustralia, Brazil, China, Germany, Spain, France
NCT06137144
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
AstraZeneca
Registry updated 13 Oct 2026
Registry record: ClinicalTrials.govPhase 114 sites
RecruitingSpain, United Kingdom, United States
NCT06173518
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Autolus Limited
Registry updated 9 Oct 2026
Registry record: ClinicalTrials.govPhase 252 sites
RecruitingAustralia, Canada, Germany, France, Italy, South Korea
NCT06806033
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Hoffmann-La Roche
Registry updated 9 Oct 2026
Registry record: ClinicalTrials.govEarly Phase 11 site
RecruitingUnited States
NCT06398457
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Registry updated 5 Oct 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingUnited States
NCT02917083
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Baylor College of Medicine
Registry updated 2 Oct 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingUnited States
NCT06176690
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Baylor College of Medicine
Registry updated 2 Oct 2026
Registry record: ClinicalTrials.govPhase 327 sites
RecruitingCzechia, Spain, France, Italy, Poland, United States
NCT07582432
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Grifols Biologicals, LLC
Registry updated 1 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07285044
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Registry updated 30 Sept 2026
Registry record: ClinicalTrials.govPhase 361 sites
RecruitingBulgaria, Croatia, Hungary, Poland, Romania, Serbia
NCT05645107
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Grifols Therapeutics LLC
Registry updated 30 Sept 2026
Registry record: ClinicalTrials.govPhase 24 sites
RecruitingUnited States
NCT03418038
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Registry updated 28 Sept 2026
Registry record: ClinicalTrials.govPhase 220 sites
RecruitingFrance
NCT04935684
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
University Hospital, Clermont-Ferrand
Registry updated 21 Sept 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT05615636
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
M.D. Anderson Cancer Center
Registry updated 18 Sept 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUganda
NCT07576725
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Registry updated 17 Sept 2026
Registry record: ClinicalTrials.govPhase 17 sites
RecruitingUnited States
NCT05798897
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Marker Therapeutics, Inc.
Registry updated 15 Sept 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingDenmark
NCT07817641
Proton Therapy for Mediastinal Lymphoma (PROMLY)
Copenhagen University Hospital, Rigshospitalet
Registry updated 14 Sept 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States76 open trials
- Italy28 open trials
- Spain26 open trials
- France21 open trials
- Germany17 open trials
- Poland15 open trials
- Australia11 open trials
- United Kingdom10 open trials
- China10 open trials
- Netherlands10 open trials
- Belgium8 open trials
- Czechia7 open trials
- Denmark6 open trials
- South Korea6 open trials
- Russia6 open trials
- Japan5 open trials
- Taiwan5 open trials
- Brazil5 open trials
- Canada5 open trials
- Israel4 open trials
- Sweden4 open trials
- Greece3 open trials
- Hungary3 open trials
- Romania3 open trials
- India3 open trials
- Moldova2 open trials
- Ukraine2 open trials
- Portugal2 open trials
- New Zealand2 open trials
- Austria2 open trials
- Finland2 open trials
- Georgia1 open trial
- Argentina1 open trial
- Türkiye1 open trial
- Chile1 open trial
- Hong Kong1 open trial
- Serbia1 open trial
- Bulgaria1 open trial
- Bosnia and Herzegovina1 open trial
- Croatia1 open trial
- Uganda1 open trial
- Ireland1 open trial
- Slovakia1 open trial
- Kazakhstan1 open trial
- Mexico1 open trial
- Egypt1 open trial
- Jamaica1 open trial
- Lithuania1 open trial
- Malawi1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Brescia, Italy
16 trials · 12 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Status changed: Completed → Running, not recruiting
NCT06667687 · Phase 1 · Australia, Denmark, Spain, United Kingdom, Israel, Japan
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567 · Phase 1/2 · Czechia, Germany, Denmark, Spain, France, Italy
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05424822 · Phase 1 · Australia, China, Denmark, France, Israel, Japan
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496 · Phase 1 · Belgium, China, Spain, France, Israel, Italy
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 2
NCT05283720 · Phase 2 · China, Czechia, Germany, Denmark, Spain, France
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 1
NCT05216835 · Phase 1 · Canada, Denmark, Spain, France, United Kingdom, Italy
Source: ClinicalTrials.govOpened for recruitment
NCT03356054 · Phase 1/2 · Belgium, Spain, Netherlands
Source: ClinicalTrials.govPhase changed: Phase 2 → Phase 1/2
NCT03356054 · Phase 1/2 · Belgium, Spain, Netherlands
Source: ClinicalTrials.govClosed for recruitment
2023-507728-22-00 · Phase 1 · Belgium, Denmark, Spain, Italy, Poland
Source: EU CTISClosed for recruitment
NCT03356054 · Phase 1/2 · Belgium, Spain, Netherlands
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 1/2Ended 13 Oct 2026
Phase 2Ended 15 Sept 2026
Completed37 participants
NCT04981899
PET-Adapted Low-Dose Nivolumab With NICE-40 for Relapsed/Refractory Classical Hodgkin Lymphoma
Phase 1Ended Jul 2026
Completed36 participants
NCT01333046
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
No phaseEnded Jul 2026
Stopped early51 participants
NCT01188915
Personalised Program for Women Treated for Hodgkin Disease
Reason given: Sponsor decision
Phase 1Ended 27 Jul 2026
Completed66 participants
2024-512390-27-00
A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin’s Lymphoma (NHL)
No phaseEnded 9 Jul 2026
Completed44 participants
NCT05550948
Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer
No phaseEnded 2 Jun 2026
Completed118 participants
NCT01868451
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Phase 1/2Ended 4 May 2026
Completed160 participants
NCT06561425
A study evaluating the safety and efficacy of GLPG5101 (19CP02) in subjects with non-Hodgkin lymphoma
Phase 1Ended 23 Apr 2026
Completed33 participants
2024-517756-35-00
A study to learn about the study medicine called PF-08046032 in people with advanced cancers.
Phase 1Ended 8 Apr 2026
Completed48 participants
NCT06254495
A safety study of PF-08046044/SGN-35C in adults with advanced cancers
Phase 1Ended 13 Feb 2026
Completed25 participants
NCT00641381
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
Phase 1Ended 10 Feb 2026
Stopped early9 participants
NCT06761586
A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)
Reason given: Patient recruitment problems
Phase 1Ended 4 Feb 2026
Phase 3Ended 3 Feb 2026
Completed330 participants
NCT03570892
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Phase 3Ended 2 Feb 2026
Completed1334 participants
NCT01712490
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Phase 1/2Ended 30 Jan 2026
Phase 1/2Ended 28 Jan 2026
Stopped early137 participants
NCT03598608
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
Reason given: Business Reason
Phase 1Ended 21 Jan 2026
Completed86 participants
NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Phase 3Ended 14 Jan 2026
Phase 2Ended 8 Jan 2026
Show more
Phase 1/2Ended 23 Dec 2025
Completed803 participants
NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study. · Cancer chemotherapy and pharmacology, 2026
- Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial. · The Lancet. Haematology, 2026
- Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL. · American journal of hematology, 2026
Phase 1/2Ended 3 Dec 2025
Completed35 participants
2023-503715-14-00
Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069)
Phase 1Ended 19 Nov 2025
No phaseEnded 17 Nov 2025
Completed645 participants
NCT03935282
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
Phase 1Ended 5 Nov 2025
Completed50 participants
NCT03259503
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
Phase 1/2Ended 27 Oct 2025
Completed161 participants
NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Phase 2Ended 13 Oct 2025
No phaseEnded 30 Sept 2025
Phase 1Ended 25 Sept 2025
Completed114 participants
NCT03573310
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
Phase 1Ended 9 Sept 2025
Completed147 participants
NCT04540796
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Phase 1Ended 4 Sept 2025
Completed45 participants
NCT05216835
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 2Ended 31 Aug 2025
Completed27 participants
NCT03331731
A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma
Phase 2Ended 29 Aug 2025
Stopped early8 participants
NCT04788043
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Reason given: Discontinuation of magrolimab development
Phase 1Ended 25 Aug 2025
Completed94 participants
NCT04772989
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
Phase 1Ended 21 Aug 2025
Completed200 participants
NCT02290951
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
Phase 1Ended 5 Aug 2025
Completed13 participants
NCT04681105
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
No phaseEnded 1 Aug 2025
Completed200 participants
NCT07120217
Breast Cancer Risk Investigation in Grown-up Hodgkin Lymphoma Patients Treated With MBVD. Multicenter Retrospective Study on ≥200 Adult Female HL Patients Treated With ≥1 MBVD Cycle (NPLD, Bleomycin, Vinblastine, Dacarbazine). It Investigates Breast Cancer Incidence Post-treatment.
No phaseEnded Jul 2025
Completed10 participants
NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Phase 1/2Ended 28 Jul 2025
Completed45 participants
NCT02227199
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 1Ended 15 Jul 2025
Completed35 participants
NCT06120504
A safety study of PF-08046045/SGN-35T in adults with advanced cancers
Phase 2Ended 13 Jun 2025
Stopped early25 participants
NCT05883449
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
Reason given: Due to sponsor decision
No phaseEnded 9 Jun 2025
Completed10 participants
NCT05205512
Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial
Phase 1Ended 28 May 2025
Completed85 participants
NCT04210219
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Phase 1Ended 22 May 2025
Completed226 participants
NCT03900598
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Phase 2Ended 3 May 2025
Stopped early150 participants
NCT03246906
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Reason given: Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.
Phase 1/2Ended 30 Apr 2025
Completed3 participants
NCT03739619
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 2Ended 18 Apr 2025
Completed46 participants
NCT03434730
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Phase 1/2Ended 25 Mar 2025
Completed34 participants
NCT02356159
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase 2Ended 24 Mar 2025
Completed78 participants
NCT02988466
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Phase 1Ended 26 Feb 2025
Stopped early69 participants
NCT03779113
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Reason given: Study terminated by sponsor
Phase 2Ended 20 Feb 2025
Withdrawn before start0 participants
NCT04373083
Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma
Reason given: Business Decision
Phase 1Ended 13 Feb 2025
Completed45 participants
NCT04876092
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL
Phase 2Ended Jan 2025
Withdrawn before start0 participants
NCT02115126
Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant
No reason given in the registry.
Phase 3Ended 31 Jan 2025
Stopped early130 participants
NCT05181540
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
Reason given: Interim analysis showed lack of efficacy
Phase 1Ended 16 Jan 2025
Completed75 participants
NCT04657224
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Phase 2Ended 8 Jan 2025
Stopped early29 participants
NCT04758650
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis
Reason given: Delay in recruitment
No phaseEnded 8 Jan 2025
Completed137 participants
NCT02815137
Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma
Phase 2Ended 8 Jan 2025
Completed28 participants
NCT02824029
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
No phaseEnded 6 Jan 2025
Completed1753 participants
NCT03904134
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Phase 2Ended 31 Dec 2024
Completed115 participants
NCT03615664
The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD
Not medical advice. fetched 10 Nov 2026